New Drugs

US FDA Approves Expanded Indication for Novartis Leqvio (inclisiran) to Include Treatment of Adults with High LDL-C and Who Are At Increased Risk of Heart Disease

Written by David Miller

Expanded indication now enables broader use of Leqvio for LDL-C reduction in patients with primary hyperlipidemia (high LDL-C) 1 Leqvio can now be used earlier in LDL-C treatment as an adjunct to diet and statin therapy for patients who have not…Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]